Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
This study has been completed.
Study NCT00086125 Information provided by Merck
First Received on June 24, 2004. Last Updated on July 7, 2011
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hematologic Malignancies
Leukemia
Myelodysplastic Syndromes
Myeloid Metaplasia
Lymphoma
Additional conditions recognized in this trial
Hematologic Neoplasms
Metaplasia
Neoplasms
Preleukemia
Primary Myelofibrosis
More general conditions related to this trial
Bone Marrow Diseases
Hematologic Diseases
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Myeloproliferative Disorders
Neoplasms by Histologic Type
Neoplasms by Site
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
ridaforolimus
Additional drug interventions recognized in this trial
Sirolimus
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Merck
Ariad Pharmaceuticals
Back to top of Main Content
